Cho cell media

The depth of our bioavailability (BA) enhancement offering makes us a leader in addressing addressing low solubility, low bioavailability and dissolution rate issues. We work collaboratively with our customers to advance compounds, or re-purpose existing compounds, across a full range of API properties and...

Inhaled drug products for nasal or pulmonary delivery continue in popularity due to the prevalence of respiratory diseases around the globe. Additionally, the lung’s absorptive capacity continues to be explored as an attractive delivery point for both local and systemic applications. Particle engineering, ...

Use of Microreaction Technology (MRT) may lower product cost of goods and increases yield and throughput of a manufacturing facility. This technology is able to perform hazardous, high temperature and pressure reactions, as well as those containing unstable or extremely reactive elements. Using MRT, these ...

At any point along your product development path, Lonza—™s Bioassay Services can help clients with immediate support for specific biological assay development. We work with our clients to overcome any quality, regulatory, or security challenges. For biopharmaceutical and cell therapy manufacturing, L...

Lonza Biologics Inc offers wide range of pharma products and services which includes biological assays. It belongs to pharma & biotech, bioassay services category. It includes cell proliferation, cell permeability, apoptosis, cell differentiation, cell survival/cytotoxicity, immunoassays: elisa, flow cytom...

Lonza Biologics Inc offers wide range of pharma products and services which includes biopreservation, fill and finish. It belongs to cell therapy products and services category. It recognize the unique time constraints associated with converting a cultured cell harvest into a formulated cell therapy product.

Lonza Biologics Inc offers wide range of pharma products and services which includes nucleofector™ devices. It belongs to bioresearch transfection services and produtcs category. It includes 4d-nucleofector™ system, 96-well shuttle™ system, ht nucleofector™ system, nucleofector™ 2b...

Lonza Biologics Inc offers wide range of pharma products and services which includes custom powdered media . It belongs to upstream serum-free media and feed formulations services and products category. Features: non animal origin facility, relative humidity, consistent particl size distribution, batch cap...

Lonza Biologics Inc offers wide range of pharma products and services which includes nucleofector™ kit accessories. It belongs to bioresearch transfection services and produtcs category. . It includes nucleofector™ plus supplement, mouse t cell nucleofector™ medium, pmaxcloning™. It is ...

Lonza Biologics Inc offers wide range of pharma products and services which includes human mesenchymal stem cells & media. It belongs to primary and adult stem cells adult stem cells & media services & products category. It includes hmsc human mesenchymal stem cells, hmsc mesenchymal stem cell adipogenic d...

Lonza Biologics Inc offers wide range of pharma products and services which includes nucleofector™ technology. It belongs to bioresearch transfection services and produtcs category. It is a technology based on the momentary creation of small pores in cell membranes by applying an electrical pulse (ele...

Lonza Biologics Inc offers wide range of pharma products and services which includes pluripotent stem cell services. It belongs to pluripotent stem cells services category. It includes pharmaceutical companies looking to implement more biologically relevant cell models into their screening campaigns, trans...

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

Enabling a healthier world.

The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies

A large and increasing fraction of orally administered small molecules in pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate. To address this trend, evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Selecting the appropriate technology for your compound requires careful consideration of the compound physicochemical properties, target dose and pharmacokinetic profile, as well as overall market image. In this on-demand webinar, hear about some of the most common bioavailability-enhancing technologies for poorly soluble compounds and a strategic framework for identifying and selecting the appropriate technology. A case study is presented.

The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects

Solid-form screening and characterization is a crucial part of drug substance development and pre-formulation. In this webcast, experts will discuss many aspects of solid-form screening including in-silico screening, which can save time and speed up the solid-form development process. A case study will review the in-silico screening of cocrystals of a pharmacophore using hydrogen bond energies and hydrogen bond propensities. A second case study will examine the cocrystallization of nutraceuticals and their versatile use as conformers.

The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies

As the pace of drug development accelerates, choosing the right early-phase partner is more critical than ever. Lonza is investing in the future of early development through a significant expansion at our Visp site, purpose-built to support fast, flexible, and integrated early-phase programs. In this presentation, we’ll showcase how our latest offerings—from SFS and AI-enabled route scouting to PBBM modeling, high-throughput experimentation, and our new Design2Optimize™ platform—work in synergy to streamline decision-making, reduce risk, and accelerate timelines. A key enabler of this innovation is the integration of robotic manufacturing and automated high-throughput experimentation, which together deliver scalable, data-rich workflows that enhance predictability and speed. Learn how Lonza’s integrated services support more robust candidate progression from preclinical through Phase I and beyond. Discover why global innovators are choosing Lonza not just for scale, but for smart, strategic collaboration at the earliest and most critical stages of development.

The new production line at Guangzhou site will supply global and domestic companies with clinical and commercial batches

The European region has historically maintained a prominent role in global off-patent API manufacturing. However, it is apparent that unique constraints are linked to API manufacturing in the European market. In this presentation, we will delve into:
Exploring the challenges and opportunities of off-patent API manufacturing in Europe The significance of fortifying local production capabilities to bolster the European competitive edge in this sector Providing valuable insights that contribute to shaping the future of off-patent API manufacturing in Europe, ensuring resilience at a local level while maintaining global relevance

Tech transfer is a crucial phase that converts clinical promise into commercial gain but pressure on sponsors to reduce time to market in the age of COVID-19 means CDMOs have to be on top of their game to deliver. What are the latest innovations to solve tech transfer challenges?

Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.

Opportunities for contract development and manufacturing organisations (CDMOs) in China continue to grow but many questions remain over what the future of the sector will look like in the world's second largest pharmaceutical market.

Explore the series of Learning Labs at CPHI North America across several product innovation categories in which thought leaders at our exhibitors showcase their extensive expertise in all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma ingredients, drug delivery and packaging.

The expansion of mid-scale capacity will enable the company to offer a smooth transition between early-phase and large-scale commercial production

While the COVID-19 pandemic has created even greater demand for partnerships, CDMOs need to be aware that the needle has shifted, creating both opportunities and challenges and changing how the services industry does business

Drug substance production line expected to be operational by end of 2021 as part of CDMO’s expanded collaboration with biotech